Amgen Hit With $50M Infringement Verdict Over Leukemia Drug

By Dani Kass · December 18, 2024, 6:18 PM EST

Germany's Lindis Biotech has persuaded a Delaware federal jury that Amgen should pay $50.3 million in damages for encouraging healthcare providers to infringe the Munich company's immunotherapy patents through administering the...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Lindis Biotech, GmbH v. Amgen Inc.

Case Number

1:22-cv-00035

Court

Delaware

Nature of Suit

Patent

Date Filed

January 10, 2022